Immunohistochemical evaluation of PTEN protein in patients with endometrial intraepithelial neoplas1a compared to endometrial adenocarcinoma and proliferative phase endometrium

Objective: The aim of this study was to reclassify endometrial hyperplasia cases and examine PTEN protein immunoreactivity compared to cases with endometrial adenocarcinoma and proliferative endometrium.

Design: Endometrial samples from 37 women with endometrial hyperplasia with atypia were reclassified as endometrial intraepithelial neoplasia (EIN). Eighteen were complex and 19 were simple endometrial hyperplasia. Twenty-our cases of EIN, ten endometrial adenocarcinoma cases and ten proliferative phase endometrium sections were immunostained for PTEN expression. PTEN expression was documented according to the degree of immunoreactivity as complete loss, partial loss and present.

Results: Twenty-four of 37 (64%) women with endometrial hyperplasia were reclassified as EIN. Complete loss of PTEN immunoreactivity was found in only one of the 24 EIN patients (4.2%), partial loss in eight of 24 (33.3%) and present in 15 of 24 (62.5%). There were no difference in PTEN immunoreactivity between EIN, endometrial adenocarcinoma and endometrial proliferation (p = 0.342). PTEN immunoreactivity was partially lost in seven and present in three of the patients with endometrial adenocarcinoma. None of the patients expressed complete loss of PTEN immunoreactivity in this group.

Conclusion: EIN classification may provide a better and more objective assessment of endometrial hyperplasia cases. PTEN expression showed no differences among the cases of EIN, endometrial carcinoma and proliferative phase endometrium.

PTEN; Endometrial intraepithelial neoplasia

[1] Jeyarajah A., Oram D., Jacobs I.: "Molecular events in endometrial carcinogenesis". Int. J. Gynecol. Cancer, 1996, 6, 425.

[2] Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A. et al.: "Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers". J. Natl Cancer Inst., 2000, 92, 924.

[3] Kong D., Suzuki A., Zou T.T., Sakurada A., Kemp L.W., Wakat suki S., Zou T.T. et al.: "PTEN is frequently mutated in primary endornetrial carcinoma". Nat. Genet., I 997, 17, 143.

[4] Bussaglia E., de! Rio E., Matias-Guiu X., Prat J.: "PTEN mutations in endornetrial carcinoma. A molecular and clinicopathologic analysis of 38 cases". Hum. Pathol., 2000, 31, 312.

[5] Mutter L.G., Lin M., Fitzgerald J.T., Kum J.B.: "Changes in endometrial PTEN expression throughout the human menstrual cycle". J. Clin. Endocrinol. Metabol., 2000, 85, 2334.

[6] Mutter G.L., Boynton K.A., Faquin W.C., Ruiz R.E., Jovanovic AS.: "Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer". Cancer Res., 1996, 56, 4483.

[7] Mutter G.L., Baak J.P., Crum C.P., Richart R.M., Ferenczy A., Paquin W.C.: "Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry". J. Pathol., 2000, 190, 462.

[8] Mutter G.L.: "Diagnosis of premalignant endometrial disease". J. Clin. Pathol., 2002, 55, 326.

[9] Mutter G.L.: "PTEN, a protean tumor suppressor". Am. J. Pathol., 2001, 158, 1895.

[10] Mutter G.L., Ince T.A., Baak J.P., Kust G.A., Zhou X.P., Eng C.: "Molecular identification of latent precancers in histologically normal endometrium". Cancer Res., 2001, 6, 4311.

[11] Levine R.L., Cargile C.B., Blazes M.S., Van Rees B., Kurman R.J., Ellenson L.H.: "1998 PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to endometrioid carcinoma". Cancer Res., 1998, 58, 3254.

[12] Maxwell G., Risinger J., Gumbs J.: "Mutation of the PTEN tumor supressor gene in endometrial hyperplasias". Cancer Res., 1998, 58, 2500.

[13] Obata K., Morland S.J., Watson R.H., Hithcock A., ChenevmxTrench G. Thomas E.J., Campbell LG.: "Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors". Cancer Res., 1998, 58, 2095.

[14] Cantley L.C., Neel B.G.: "New insights into tumor supression PTEN supresses tumor formation by restraining the phosphoinositide 3-kinase/AILT pathway" Proc. Natl. Acad. Sci, USA, 1999, 96, 4240.

[15] Myers M.P., Pass I., Batty l.H., Van der Kaay J., Stolarov J.P., Hemmings B.A.: "The lipid phosphatase activity of PTEN is critical for its tumor supressor function". Proc. Natl. Acad Sci, USA, 1998, 95, 13513.

[16] Lin W.M., Forgac E., Warshal D.P., Yeh LT., Martin J.S., Asfaq R., Muller J.Y.: "Lossof heterozygosity and mutational analysis of the PTEN/MMACI gene in synchronous endometrial and ovarian carcinomas". Clin. Cancer Res., 1998, 4, 2577.

[17] Risinger J. I., Hayes A.K., Berchuck A., Barret J . C "PTEN/MMACl mutations i n endometrial cancers". Cancer Res., 1997, 57, 4736.

[18] Tashiro H., Blazes M.S., Wu R.: "Mutations in PTEN are frequent in endometrial carcnoma but rare in other common gynecological malignancies". Cancer Res., 1997, 57, 3935.

[I9] Yoshinga K., Sasano H., Furukawa T.: "The PTEN, BAX, and IGFIIR genes are mutated in endometrail atypical hyperplasia". J. Cancer Res., 1998, 89, 985.

[20] Matias-Guiu X., Catasus L., Bussaglia E., Lagarda H., Garcia A., Pons C. et al.: "Molecular pathology of endometrial hyperplasic and carcinoma". Hum Pathol., 2001, 32, 569.

[21] Sherman M.E., Bur M.E., Kurman R.J.: "p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of turnorigenesis". Hum. Pathol., 1995, 26, 1268.

[22] Ali I.U.: "Gatekeeper for endometrium: the PTEN tumor suppressor gene". J. Natl. Cancer Inst., 2000, 92, 861.

[23] Guzeloglu-Kayisli 0., Kayisli U.A., Al-Rejjal R., Zheng W., Luleci G., Arici A.: "Regulation of PTEN (phosphatase and tensin hornolog deleted on chromosome 10) expression by estradiol and progesterone in human endornetriurn". J. Clin. Endocrinol. Metab., 2003, 88, 5017.

[24] Liliental J., Moon S.Y., Lesche R., Marnillapalli R., Li D., Zheng Y., Sun H., Wu H.: "Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rael and Cdc42 GTPases". Curr. Biol., 2000, 10, 401.

[25] Terakawa N., Kanamori Y., Yoshida S.: "Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer". Endocr. Re/at. Cancer, 2003, 10, 203.